CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Josh Blacher

Profile

Josh Blacher

interim Chief Financial Officer, Imunon, Inc.

In the seat, on an interim basis. First published here October 28, 2026; built from records as of October 28, 2026.

Josh Blacher has been interim Chief Financial Officer of Imunon, Inc. since July 1, 2026, according to the company's filing of June 30, 2026.1

The filing gives Josh Blacher's previous role as employee of Danforth at Danforth Health, Inc.1 Josh Blacher joined from outside Imunon, Inc., by the record's reading of the filing.1

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Imunon, Inc. (IMNN)
Pharmaceutical Preparations
interim Chief Financial OfficerIn the seat, on an interim basis1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. July 1, 2026effective

    Imunon, Inc. named Josh Blacher interim Chief Financial Officer, effective July 1, 2026. Profile of Jeffrey Church.

    Church’s retirement, effective July 1, 2026, the Company appointed Josh Blacher to serve as the Company’s new interim Chief Financial Officer under a master services agreement (the “Agreement”), dated June 24, 2026, between the Company and Danforth Health, […]

    [1] Filing by Imunon, Inc., filed with the SEC on June 30, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Current report filed with the SEC, Imunon, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 30, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Josh Blacher wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.